SNB 101
Alternative Names: SN-38 - SN BioScience; SNB-101Latest Information Update: 25 May 2026
At a glance
- Originator SN BioScience
- Class Antineoplastics; Camptothecins; Indolizines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Yes - Gastric cancer; Small cell lung cancer; Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Small cell lung cancer
- Phase I Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 14 May 2026 EMA approves IND application for SNB 101 in Small cell lung cancer (Combination therapy)
- 14 May 2026 SN Bioscience plans to file an additional CTA for a separate study involving another immunotherapy combination within this year
- 14 May 2026 Efficacy data from a phase I trial in Small cell lung cancer released by SN BioScience